# A Phase II Study Evaluating the Efficacy and Safety of ABSK021 (Pimicotinib)) in the Treatment of cGvHD Chronic Graft Versus Host Disease (cGvHD)

> **NCT06186804** · PHASE2 · ENROLLING_BY_INVITATION · sponsor: **Abbisko Therapeutics Co, Ltd** · enrollment: 64 (estimated)

## Conditions studied

- cGvHD

## Interventions

- **DRUG:** ABSK021

## Key facts

- **NCT ID:** NCT06186804
- **Lead sponsor:** Abbisko Therapeutics Co, Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2023-05-30
- **Primary completion:** 2026-10-30
- **Final completion:** 2026-12-30
- **Target enrollment:** 64 (ESTIMATED)
- **Last updated:** 2024-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06186804

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06186804, "A Phase II Study Evaluating the Efficacy and Safety of ABSK021 (Pimicotinib)) in the Treatment of cGvHD Chronic Graft Versus Host Disease (cGvHD)". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT06186804. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*